ATI Extends Agreement with BWXT to Support U.S. Naval Nuclear Propulsion Program
Get Alerts ATI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.8%
Revenue Growth %: +7.0%
Join SI Premium – FREE
Five-year strategic material agreement delivers critical defense materials through 2030
"For more than 40 years, ATI has delivered advanced materials that enable naval systems built by BWXT to operate with unmatched performance, reliability, and protection," said ATI President and CEO
ATI's leadership in manufacturing specialty materials used in nuclear applications spans nearly seven decades, dating back to some of the U.S. Navy's first nuclear-powered submarines. As the world's largest producer of specialty materials, ATI combines deep materials science expertise with proprietary process technologies to deliver highly engineered materials essential to BWXT's mission.
ATI is a strategic defense partner across air, land, sea, and missile platforms, providing high-performance titanium, nickel-based alloys, and specialty materials that power and protect next-generation systems in the most demanding environments.
ATI: Proven to Perform
ATI (NYSE: ATI) is a global producer of high-performance materials and solutions for the aerospace & defense markets, and specialty energy. We're solving the world's most difficult challenges through materials science. We partner with our customers to deliver extraordinary materials that enable their greatest achievements: their products fly higher and faster, burn hotter, dive deeper, stand stronger and last longer. Our proprietary process technologies, unique customer partnerships and commitment to innovation deliver materials and solutions for today and the evermore challenging environments of tomorrow. We are proven to perform anywhere. ATImaterials.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ati-extends-agreement-with-bwxt-to-support-us-naval-nuclear-propulsion-program-302798115.html
SOURCE ATI
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
- Canadian Health IT Buyers Bring a Connected-Care Growth Agenda to e-Health26: Interoperability, Trusted Data and Measurable ROI
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share